Literature DB >> 31177130

Should We Cease to Perform Salvage Hysterectomy After Chemoradiation and Brachytherapy in Locally Advanced Cervical Cancer?

Marie Gosset1, Cyrus Chargari2,3, Erica Bentivegna4, Alexandra Leary5, Catherine Genestie6, Amandine Maulard4, Philippe Morice4,3, Sebastien Gouy4.   

Abstract

BACKGROUND/AIM: We evaluated patients undergoing salvage hysterectomy after brachytherapy (BT) following concomitant chemoradiation (CRT) for locally advanced cervical cancers (LACC), when residual disease was suspected. PATIENTS AND METHODS: From 2004 to 2013, 29 patients had a radical hysterectomy at the Gustave Roussy for suspicion of clinical and/or radiological residual disease. Outcomes, morbidities and the accuracy of the evaluation of response to CRT and BT were evaluated.
RESULTS: The rate of complications grade>IIIa was 24%, with no difference between the 14 patients with histological residual disease and the 15 with a complete response. Magnetic resonance imaging (MRI) and positron emission tomography-computed tomography (PET-CT) revealed a sensitivity of 92% and 100%, but a poor specificity of less than 40%. Three recurrences occurred in patients with residual disease (brain, rectosigmoid colon, peritoneum and lung).
CONCLUSION: The clinical examination, MRI and PET-CT are suboptimal for diagnosing residual disease after CRT and BT. The morbidity of adjuvant hysterectomy is high and does not prevent recurrences. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Locally advanced cervical cancer; brachytherapy salvage hysterectomy; chemoradiation therapy; morbidity

Mesh:

Year:  2019        PMID: 31177130     DOI: 10.21873/anticanres.13421

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

Review 1.  Current Standards in the Management of Early and Locally Advanced Cervical Cancer: Update on the Benefit of Neoadjuvant/Adjuvant Strategies.

Authors:  Yuedan Zhou; Elie Rassy; Alexandre Coutte; Samir Achkar; Sophie Espenel; Catherine Genestie; Patricia Pautier; Philippe Morice; Sébastien Gouy; Cyrus Chargari
Journal:  Cancers (Basel)       Date:  2022-05-16       Impact factor: 6.575

2.  Chemoradiotherapy alone vs. chemoradiotherapy and hysterectomy for locally advanced cervical cancer: A systematic review and updated meta-analysis.

Authors:  Weijia Lu; Canxiong Lu; Zhiwu Yu; Lei Gao
Journal:  Oncol Lett       Date:  2020-12-31       Impact factor: 2.967

3.  Propensity score-matched analysis of systemic chemotherapy versus salvage hysterectomy for persistent cervical cancer after definitive radiotherapy/concurrent chemoradiotherapy.

Authors:  Munetaka Takekuma; Fumiaki Takahashi; Seiji Mabuchi; Wataru Kudaka; Koji Horie; Mariko Ikeda; Ayumi Shikama; Akira Mitsuhashi; Shoji Nagao; Shiro Suzuki; Mika Mizuno; Shin Nishio; Hideki Tokunaga; Yukinobu Ota; Takahiro Kasamatsu; Ryo Kitagawa; Takafumi Toita; Hiroaki Kobayashi; Mitsuya Ishikawa; Nobuo Yaegashi
Journal:  BMC Cancer       Date:  2020-11-30       Impact factor: 4.430

4.  Diagnostic Framework of Pelvic Massive Necrosis with Peritonitis following Chemoradiation for Locally Advanced Cervical Cancer: When Is the Surgery Not Demandable? A Case Report and Literature Review.

Authors:  Elisabetta Sanna; Giacomo Chiappe; Fabrizio Lavra; Sonia Nemolato; Sara Oppi; Antonio Macciò; Clelia Madeddu
Journal:  Diagnostics (Basel)       Date:  2022-02-09

5.  MRI accuracy and interobserver agreement in locally advanced cervix carcinoma.

Authors:  Amalia Jacquot; Céline Chauleur; Anne-Sophie Russel-Robillard; Fabien Tinquaut; Sandrine Sotton; Nicolas Magne; Guillaume Etievent
Journal:  Br J Radiol       Date:  2021-07-08       Impact factor: 3.629

6.  Successful treatment of locally advanced bulky cervical cancer complicated by irreducible complete uterine prolapse: A case report.

Authors:  Dong Hyung Lee; Jong Kil Joo; Dong Soo Suh; Byung Sup Shin; Seo Yoon Hwang; Ki Hyung Kim
Journal:  Medicine (Baltimore)       Date:  2022-01-21       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.